Alexion: Today's opening is confirming the bullish assumptionGood spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud).
I was waiting for today's opening to confirm a bullish position.
Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
PHARMA
Biogen: Further GrowthAfter the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase.
I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an exciting phase, testing the high line of the cloud with a bullish configuration, as also confirmed by the Stochastic.
The upward trend is also confirmed by fundamental analysis. Biogen counts on a strong collaboration with Roche in oncology, and on growing revenues thanks to Ocrevus (Multiple Sclerosis), as well as to a significant pipeline.
Furthermore, the complexity of Biogen's drugs makes the production of Biosimilars difficult.
Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
PFE Bump and Run!PFE is a large pharmaceutical company that specialises in biopharmaceuticals. As you can see there has been a large bump and run from the upward trend in the past, which led to a death-cross. Gaussian channel shows a clear upward trend. Green fractal indicates a follow up bump and run.
$MNK Go timeAscending Wedge Reversal.
Volume is there and ready to go.
Generic opioid manufacturers have been beaten down recently over fear of a copious monetary fine, but MNK has an established diverse profile.
Do NOT miss this stock when it runs.
Break above $4.15 and were off
Long Term Target: $12.90
VSTM - Bear Trend ReversalBear Trend Reversal - Long term downtrend rejected with bullish RSI divergence on the weekly.
These hops off a long-term bear trend reversals can be swift and powerful. I've played these before and won (DAN...TQQQ after '18 Christmas)..but I've also played these and lost (MAXR).
I've previously played these directly on the instrument, but this time I'm playing this with 10 buys of $2 March 20, 2020 calls. Hoping to see a continued surge of implied volatility for these options as I don't plan on holding them through expiry. That being said, I've yet to really win on any of my options trades...but IV is on the up and up since my purchase so we'll just have to wait'n'see.
DRG - Pharmaceuticals Finding Relative StrengthDRG broke out of a consolidation period during yesterday's trading & continued its bullish momentum today. The industry is also beginning to find relative strength against the SPX. This could be an industry worth looking around in to find some stocks to provide alpha if it continues to strengthen.
Hikma Pharmaceuticals - Injecting some bullish momentum.Buy Hikma Pharmaceuticals (HIK.L)
Hikma Pharmaceuticals PLC develops, manufactures, and markets pharmaceutical products. The Company offers branded and non-branded generic and in-licensed pharmaceutical products. Hikma Pharmaceuticals serves customers worldwide.
Market Cap: £4.79Billion
The long-term trend on Hikma remains bullish. The corrective move lower in recent weeks has found some support at the 38.2% Fibonacci level. The posting of a bullish engulfing candle while simultaneously breaking from a wedge pattern is bullish for short term sentiment. Further upside is expected from here, targeting the previous highs at 2345p from 15th March 2017.
Stop: 1920p
Target 1: 2210p
Target 2: 2345p
Target 3: 2400p
Interested in UK Stocks?
Join our free Telegram channel for up to date analysis on the best main market opportunities in the UK right now - t.me
ALKS BUY 03.09.2019BUY signal at 20.98 $
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas.
If you want to see more history of this strategy, I will able to show you if you request me.
ATTENTION this strategy may has downtrend about 20%, so you can split your buy order, that you have not big downtrend.
__________________________________________________________________________
You can use the signals independently or like indicator of trends together with other indicators in your trading strategy.
Know that the success of your strategy that based on those signals depends from your money management and the additional conditions that you make in these strategies.
You use these signals inside your strategies at your own risk.
The chart shows the last trades on the product + the last signal.
I have several strategies for different products, and I want to show you proof of it works on history, and you will be able to see it, when returns to that profile.
Therefore, subscribe and watch for that profile.
The signals rare but useful.
$AMPE Ampio Pharmaceuticals Inc A Good Risk/Reward PlayWe are really liking the chart on $AMPE. You have the rounding bottom and there looks to be accumulation going on.
Currently trading at $.62 a share, the 52-week low is $.35 a share.
We believe $AMPE has breakout written all over it and there is an upcoming catalyst that can send the stock flying higher. The company is due to hear from the FDA shortly. Here's what the company said last month in its update:
Ampio Pharmaceuticals has been in contact with the U.S. Food and Drug Administration (FDA) regarding the Special Protocol Assessment (SPA) following its re-submission of a revised protocol for AP-013, which the Company believes implements all of the Agency's recommendations provided since the beginning of the SPA review cycle. The Agency confirmed that it would make every effort to expedite this review, however due to a heavy workload, they were not able to commit to providing a response to the Company's SPA re-submission earlier than the 45-day window outlined in the Guidance for Industry Special Protocol Assessment, leading the Company to expect the response will be in mid-June rather than late May 2019, as previously predicted.
There is some debate on social channels as to when this news will hit the tape. Some are saying any day now, while others are saying after the July 4th holiday.
As always, trade with caution and use protective stops.
Good luck to all!
G1 Therapeutics RALLYEarnings/News
Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions
GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September
FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co
Analyst Actions
JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
AGN - downward channel since 2015This big Pharma has been on the decline since 2015. I see it is in the top of the channel currently. Good opportunity to short to the bottom of the channel, especially with the general market declining.